Tipranavir is a sulfonamide and can be absorbed systemically. Sulfonamides can produce severe, possibly fatal, reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome.
Tipranavir is co-administered with ritonavir.
Contra-indicated in patients with moderate or severe (Child-Pugh Class B or C) hepatic impairment.
